

The UK Oncology Nursing Society

Trustees' Report (continued)

Year Ended 31 March 2024

The trustees have pleasure in presenting their report and the unaudited financial statements of the charitable company for the year ended 31 March 2024.

Status

The charitable company is limited by guarantee, having no share capital. Under the provisions of Section 60 of the Companies Act 2006, the company is entitled to omit the word "Limited" from its name. The governing document of the charitable company is its Memorandum and Articles of Association.

The charitable company is also known as UKONS.

Objects and Activities of the Charity

The objects of the charitable company are, for the public benefit:

1. To advance health and to relieve those in need by reason of ill-health, including without limitation people affected by cancer; and
2. To advance the education of the public in the subjects of health, medical and nursing care, including without limitation the causes, effects and treatments of cancer.

Aims of the charity

- To promote excellence in the nursing care and management of all those directly and indirectly affected by cancer.
- To encourage and facilitate the personal and professional development of nurses engaged in cancer care throughout the UK and overseas through education, research and policy.
- To share information about research, learning and development opportunities with UKONS members.
- To contribute to the development of cancer policy, clinical practice and service delivery nationally and internationally.
- To foster alliances and develop UK and international networking opportunities.

Activities and achievements aligned to the charity's aims for the year 2022/24

- Continuation of the Members Interest Groups: Living with and Beyond Cancer; Acute Oncology Services; Systemic Anti-cancer Treatments; Radiotherapy; Haemato-oncology; Lead Cancer Nurses; Research
- A further Members Interest Group- 'Young and Early Career Cancer Nurses' was added in 2021 and fully established as an interest group with annual webinar activity and a Facebook and social media presence.
- Continuation of our provision of the UKONS website (www.ukons.org), catering to the needs of members and the members interest groups.
- Continued publication of fortnightly editions of UKONS 'Breaking News' bulletin, supporting practice development and career progression, which is sent to all members via e-mail. This includes cancer nurse job advertisements for UKONS members. These advertisements are provided free of charge to advertisers.
- During 2023/24 Breaking News continued to be delivered jointly between UKONS and Macmillan Cancer Care due to an ongoing and developing partnership. This was underpinned by an MOU agreed and signed by both parties, renewed in 2022.
- UKONS continues to hold the face-to-face annual conference since with increasing numbers of abstract submissions and attendance. The event focussed on a theme of 'Integrating Cancer Care'. This provided the opportunity for cancer nurses to present orally, and through posters on education, innovation and research. This year, as with the previous nine, the

The UK Oncology Nursing Society

Trustees' Report (continued)

Year Ended 31 March 2024

conference abstract booklet was made available to delegates. This is available in electronic format.

- Work continued to produce a digital application of the UKONS Systemic Anti-cancer Therapy (SACT) Competency Passport together with our partner is Tefogo Ltd. This was launched in January 2024.
- During 2023/24 UKONS continued to be a prominent member of the UK SACT Board (formally UK Chemotherapy Board) delivering guidelines across all four nations for the delivery of systemic anti-cancer therapies.
- UKONS continued to be a central organisation in promoting the ACCEND (Aspirant Cancer Career and Education Development) programme. This career framework provides guidance and structure for all health care professionals wishing to develop a career in cancer care.
- Continued to approve translations of the UKONS Acute Oncology Triage Tool as well as working to formalise and deliver electronic versions of the tool.
- The AOS interest group designed and developed an eLearning course in partnership with E learning for Health NHS England. This was launched in 2024.
- UKONS worked in partnership with the UK Acute Oncology Society and Macmillan to standardise AO education, training and assessment and advanced work on multi-professional AO competency passports. To be launched in June 2024
- Work commenced and continued on a book on the impact of the COVID pandemic in cancer care across Europe in partnership with Springer Press.
- Organised and presented education, training sessions and symposia at virtual and face-to-face events for both UKONS and other organisations throughout the year, including the UK Oncology Forum and the Oncology Professional Care Conference, British Hematology Society, International Cancer Nursing Society and the European Oncology Nursing Society.
- Further developed the activities of UKONS Champions, with Young and Early Career Cancer Nurse input into a wide range of programmes and events. The champions worked to establish a sub-group for both UKONS board alumni and Cancer Information Nurses.
- Continued to work with a wide range of industry partners and develop further relationships, extending our numbers of partners to more than 20.
- Collaborated with: NHS England, UK Oncology Forum; British Journal of Nursing; Cancer Nursing Practice, The European Oncology Nursing Society (EONS); International Society of Nurses in Cancer Care (ISNCC); and Oncology Professional Care
- Representation at the UK Chemotherapy Board; various NHS Working Groups (including those on SACT Capacity and Workforce); Macmillan Cancer Support/HEE.
- Provision of basic oncology education provided by O'Hallaran Consultancy, to all UKONS members.
- Collaboration with Macmillan Cancer Support to provide Podcasting on topical issues available through podcasting platforms and accessible worldwide.

Organisational Structure

The Board has five executive officers: President, President Elect, Past President Secretary and Treasurer. It has an additional ten full Board members who are all Trustees. New Trustees receive induction into their role on the Board.

Assessment of going concern

The charity's income is reliant on sponsorship from UKONS Partners. Income for 23/24 was reduced from the previous year but not significantly. It continues to be unpredictable for some partners and their budget constraints. The board maintain a cautious approach and these factors have been considered in budgeting resources for the next financial year.

The UK Oncology Nursing Society

Trustees' Report (continued)

Year Ended 31 March 2024

Directors and Trustees

The directors and trustees who served the company during the year and up to the date of this report were as follows:

Karen Campbell (President)
Mary Tanay (President Elect)
Mark Foulkes (Past President)
Lyndel Moore (Treasurer)
Deborah Wightman (Secretary)
Nalayini Kumaralingam
Kay Bell
Jo Bird
Tracy Wilson
Rosemary Roberts
Naomi Clatworthy
Ruth Hammond
Constance Rowell
Barry Quinn
Linda Sherwood


Reserves

The Trustees plan to retain a modest level of reserves as a contingency fund against future demands on the charity's resources.

Small Company Provisions

This report has been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

Signed on behalf of the directors

A handwritten signature in black ink, appearing to read 'Karen Campbell', with a stylized, cursive script.

Dr Karen Campbell
Director

Approved on31st August 2024

The UK Oncology Nursing Society

Unaudited Financial Statements

Year Ended 31 March 2024

Company Registration Number 06996552

Charity Registration Number 1136972

The UK Oncology Nursing Society

Financial Statements

Year Ended 31 March 2024

Contents	Page
Trustees' Report	1
Independent Examiner's Report	4
Statement of Financial Activities	5
Balance Sheet	6
Notes to the Financial Statements	7

The UK Oncology Nursing Society

Trustees' Report

Year Ended 31 March 2024

The trustees have pleasure in presenting their report and the unaudited financial statements of the charitable company for the year ended 31 March 2024.

Status

The charitable company is limited by guarantee, having no share capital. Under the provisions of Section 60 of the Companies Act 2006, the company is entitled to omit the word "Limited" from its name. The governing document of the charitable company is its Memorandum and Articles of Association.

The charitable company is also known as UKONS.

Objects and Activities of the Charity

The objects of the charitable company are, for the public benefit:

1. To advance health and to relieve those in need by reason of ill-health, including without limitation people affected by cancer; and
2. To advance the education of the public in the subjects of health, medical and nursing care, including without limitation the causes, effects and treatments of cancer.

Aims of the charity

- To promote excellence in the nursing care and management of all those directly and indirectly affected by cancer.
- To encourage and facilitate the personal and professional development of nurses engaged in cancer care throughout the UK and overseas through education, research and policy.
- To share information about research, learning and development opportunities with UKONS members.
- To contribute to the development of cancer policy, clinical practice and service delivery nationally and internationally.
- To foster alliances and develop UK and international networking opportunities.

Activities and achievements aligned to the charity's aims for the year 2023/24

- Continuation of the Members Interest Groups: Living with and Beyond Cancer; Acute Oncology Services; Systemic Anti-cancer Treatments; Radiotherapy; Haemato-oncology; Lead Cancer Nurses; Research
- A further Members Interest Group- 'Young and Early Career Cancer Nurses' was added in 2021 and fully established as an interest group with annual webinar activity and a Facebook and social media presence.
- Continuation of our provision of the UKONS website (www.ukons.org), catering to the needs of members and the members interest groups.
- Continued publication of fortnightly editions of UKONS 'Breaking News' bulletin, supporting practice development and career progression, which is sent to all members via e-mail. This includes cancer nurse job advertisements for UKONS members. These advertisements are provided free of charge to advertisers.
- During 2023/24 Breaking News continued to be delivered jointly between UKONS and Macmillan Cancer Care due to an ongoing and developing partnership. This was underpinned by an MOU agreed and signed by both parties, renewed in 2022.
UKONS continues to hold the face-to-face annual conference since with increasing numbers of abstract submissions and attendance. The event focussed on a theme of 'Integrating Cancer Care'. This provided the opportunity for cancer nurses to present orally, and through posters on

The UK Oncology Nursing Society

Trustees' Report (continued)

Year Ended 31 March 2024

education, innovation and research. This year, as with the previous nine, the conference abstract booklet was made available to delegates. This is available in electronic format. Work continued to produce a digital application of the UKONS Systemic Anti-cancer Therapy (SACT) Competency Passport together with our partner is Tefogo Ltd. This was launched in January 2024.

- During 2023/24 UKONS continued to be a prominent member of the UK SACT Board (formally UK Chemotherapy Board) delivering guidelines across all four nations for the delivery of systemic anti-cancer therapies.
- UKONS continued to be a central organisation in promoting the ACCEND (Aspirant Cancer Career and Education Development) programme. This career framework provides guidance and structure for all health care professionals wishing to develop a career in cancer care.
- Continued to approve translations of the UKONS Acute Oncology Triage Tool as well as working to formalise and deliver electronic versions of the tool.
- The AOS interest group designed and developed an eLearning course in partnership with E learning for Health NHS England. This was launched in 2024.
- UKONS worked in partnership with the UK Acute Oncology Society and Macmillan to standardise AO education, training and assessment and advanced work on multi-professional AO competency passports. To be launched in June 2024
- Work commenced and continued on a book on the impact of the COVID pandemic in cancer care across Europe in partnership with Springer Press.
- Organised and presented education, training sessions and symposia at virtual and face-to-face events for both UKONS and other organisations throughout the year, including the UK Oncology Forum and the Oncology Professional Care Conference, British Hematology Society. International Cancer Nursing Society and the European Oncology Nursing Society.
- Further developed the activities of UKONS Champions, with Young and Early Career Cancer Nurse input into a wide range of programmes and events. The champions worked to establish a sub-group for both UKONS board alumni and Cancer Information Nurses.
- Continued to work with a wide range of industry partners and develop further relationships, extending our numbers of partners to more than 20.
- Collaborated with: NHS England, UK Oncology Forum; British Journal of Nursing; Cancer Nursing Practice, The European Oncology Nursing Society (EONS); International Society of Nurses in Cancer Care (ISNCC); and Oncology Professional Care
- Representation at the UK Chemotherapy Board; various NHS Working Groups (including those on SACT Capacity and Workforce); Macmillan Cancer Support/HEE.
- Provision of basic oncology education provided by O'Hallaran Consultancy, to all UKONS members.
- Held the European Cancer Nursing Day in Edinburgh 2023 in collaboration with EONS.
- Collaboration with Macmillan Cancer Support to provide Podcasting on topical issues available through podcasting platforms and accessible worldwide.

Organisational Structure

The Board has five executive officers: President, President Elect, Past President Secretary and Treasurer. It has an additional ten full Board members who are all Trustees. New Trustees receive induction into their role on the Board.

Assessment of going concern

The charity's income is reliant on sponsorship from UKONS Partners. Income for 23/24 has increased from the previous year. Income continues to be unpredictable for some partners and their budget constraints. The board maintain a cautious approach and these factors have been considered in budgeting resources for the next financial year.

The UK Oncology Nursing Society

Trustees' Report (continued)

Year Ended 31 March 2024

Directors and Trustees

The directors and trustees who served the company during the year and up to the date of this report were as follows:

Karen Campbell (President Elect) (from 17 November 2023)

Mary Tanay

Mark Foulkes (Past President) (to 16 November 2023)

Lyndel Moore (Treasurer)

Deborah Wightman (Trustee and Secretary)

Nalayini Kumaralingam

Kay Bell

Jo Bird

Tracy Wilson

Rosemary Roberts

Naomi Clatworthy

Ruth Hammond

Constance Rowell

Verna Lavender (resigned 17 November 2023)

Barry Gerard Quinn (appointed 18 November 2023)

Linda Sherwood (appointed 18 November 2023)

Lisa Barrott (resigned 17 November 2023)

Libby Potter (resigned 31 January 2024)


Reserves

The Trustees plan to retain a modest level of reserves as a contingency fund against future demands on the charity's resources.

Small Company Provisions

This report has been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

Signed on behalf of the directors



Dr Karen Campbell
Director

Approved on 30 November 2024

The UK Oncology Nursing Society

Independent Examiner's Report to the Trustees

Year Ended 31 March 2024

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 March 2024.

Responsibilities and basis of report

As the charity's trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ("the 2006 Act").


Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Martin Hobbs BSc ACA

Francis Clark LLP
Chartered Accountants
Sigma House
Oak View Close
Edginswell Park
Torquay
TQ2 7FF

Date: 2 December 2024

The UK Oncology Nursing Society

Statement of Financial Activities (incorporating an Income and Expenditure Account)

Year Ended 31 March 2024

	Unrestricted Funds £	Restricted Funds £	Total 2024 £	Total 2023 £
Income from:				
Partnership income	147,042	-	147,042	80,833
Board activity	19,235	-	19,235	14,691
Donations	1,408	-	1,408	4,100
Grants	-	40,000	40,000	-
Other income	16,667	-	16,667	1,025
Total	184,352	40,000	224,352	100,649
Expenditure on:				
BJN Awards	277	-	277	-
CASCADE workshop	2,111	-	2,111	-
Covid 19 and Cancer book	11,402	-	11,402	-
Personalised Cancer Care Book	4,000	-	4,000	-
Pocketbook of Cancer Care Nursing	8,333	-	8,333	-
SACT passport project	56,205	2,230	58,435	20,000
Champions' workshop	-	-	-	31
EBN Health book	-	2,917	2,917	28
Palliative care booklet	-	-	-	2,450
EONS membership fee	875	-	875	893
ISNCC membership fee	248	-	248	244
Annual conference	33,122	5,000	38,122	22,500
Board meetings – Travel and subsistence	7,784	-	7,784	8,970
Other conferences	14,634	-	14,634	11,084
Entertaining/other meetings	14,346	-	14,346	11,055
MIGs	8,202	-	8,202	7,629
Administrative support	26,760	-	26,760	15,760
Secretarial services	15,000	-	15,000	330
Legal and professional	660	-	660	2,601
Stationery and admin	186	-	186	17
Website and social media	7,043	-	7,043	7,013
Accounting fees	10,320	-	10,320	5,475
Insurance	985	-	985	848
Irrecoverable VAT	10,997	-	10,997	6,931
Grants BMS AOS	1,485	35,000	36,485	15,000
Purchases	10,734	-	10,734	10,230
Total	245,709	45,147	290,856	149,089
Net income/(expenditure)	(61,357)	(5,147)	(66,504)	(48,440)
Total funds brought forward	183,660	5,147	188,807	237,247
Total funds carried forward	122,303	-	122,303	188,807

All of the incoming resources of the charity for the comparative year are unrestricted. All of the above results are derived from continuing activities. All gains and losses recognised in the year are included above. The result for the year for Companies Act purposes is equivalent to the net income / (expenditure).

The UK Oncology Nursing Society

Balance Sheet

31 March 2024

	Notes	2024 £	2023 £
Current assets			
Debtors	4	53,095	22,120
Cash at bank and in hand		151,808	252,811
		<u>204,903</u>	<u>274,931</u>
Liabilities			
Creditors falling due within one year	5	(82,600)	(86,124)
		<u></u>	<u></u>
Total assets less current liabilities		<u>122,303</u>	<u>188,807</u>
Unrestricted funds	6	122,303	183,660
Restricted funds	6	-	5,147
		<u></u>	<u></u>
Total funds		<u>122,303</u>	<u>188,807</u>


The directors are satisfied that the company is entitled to exemption from the provisions of the Companies Act 2006 (the Act) relating to the audit of the financial statements for the year by virtue of section 477, and that no member or members have requested an audit pursuant to section 476 of the Act.

The directors acknowledge their responsibilities for:

- (i) ensuring that the company keeps adequate accounting records which comply with section 386 of the Act, and
- (ii) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit or loss for the financial year in accordance with the requirements of sections 394 and 395, and which otherwise comply with the requirements of the Act relating to financial statements, so far as is applicable to the company.

These financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act.

These financial statements were approved and signed by the trustees and authorised for issue on 30 November 2024, and are signed on their behalf by:



.....
Karen Campbell
Director

Company Registration Number: 06996552

The UK Oncology Nursing Society

Notes to the Financial Statements

Year Ended 31 March 2024

1 Accounting Policies

Basis of accounting

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

a) Basis of preparation of financial statements and assessment of going concern

The financial statements have been prepared under the historical cost convention and in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The UK Oncology Nursing Society meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

The functional and presentational currency of these financial statements is sterling.

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern.

b) Income

Income is recognised when the charity has entitlement to funds, any performance conditions attached to the items of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Capital grants receivable are credited to the SOFA as they become receivable and are treated as restricted funds. The depreciation on the assets to which the grants relate is charged against these funds.

c) Fund accounting

Unrestricted funds are funds available for use at the discretion of the trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds received which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes.

d) Expenditure

Expenditure is recognised once there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably. Expenditure includes irrecoverable VAT.

e) Financial instruments

Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. The company holds the following financial instruments, all of which are considered to be basic:

- Short term debtors and creditors
- Cash and bank balances

The UK Oncology Nursing Society

Notes to the Financial Statements

Year Ended 31 March 2024

2 Related Party Transactions

During the year travel expenses of £11,919 were reimbursed to 13 trustees (2023: £12,164 to 15 trustees).

3 Company Limited by Guarantee

The company is limited by guarantee and has no share capital. In the event of a winding-up, the liability of the members is limited to £1 each. The Charity is incorporated in England and Wales. The address of its registered office is: Legalinx, 14-18 City Road, Cardiff, Wales, CF24 3DL.

4 Debtors

	2024 £	2023 £
Trade debtors	40,702	20,005
Prepayments and accrued income	5,599	2,115
VAT	6,794	-
	53,095	22,120

5 Creditors: amounts falling due within one year

	2024 £	2023 £
Accruals and deferred income	82,600	62,059
VAT payable	-	3,709
Other creditors	-	20,356
	82,600	86,124

6 Analysis of movement on funds

	Balance at 1 April 2023 £	Incoming resources £	Resources expended £	Balance at 31 March 2024 £
Total unrestricted funds	183,660	184,352	(245,709)	122,303
Restricted funds:				
Gilead	-	5,000	(5,000)	-
BMS	-	35,000	(35,000)	-
AOS education grant	2,230	-	(2,230)	-
EBN book grant	2,917	-	(2,917)	-
	188,807	224,352	(290,856)	122,303

The Gilead grant represents funds to support healthcare professionals to attend the UKONS 2023 conference

The BMS AOS grant represents funds raised towards the development of acute oncology service telephone triage E-learning modules

The AOS education grant represents funds raised for the development of a digital friendly format for UKONS guidance for assessment of patients.

The UK Oncology Nursing Society

Notes to the Financial Statements

Year Ended 31 March 2024

The EBN book grant represents funds raised for the writing and publication of a reference book entitled "Fundamentals of Cancer Care".

The restricted funds are all held as cash at bank and in hand.

Prior year analysis of movement on funds

	Balance at 1 April 2022 £	Incoming resources £	Resources expended £	Balance at 31 March 2023 £
Total unrestricted funds	232,072	100,649	(149,061)	183,660
Restricted funds:				
AOS education grant	2,230	-	-	2,230
EBN book grant	2,945	-	(28)	2,917
	<u>237,247</u>	<u>100,649</u>	<u>(149,089)</u>	<u>188,807</u>

The AOS education grant represents funds raised for the development of a digital friendly format for UKONS guidance for assessment of patients.

The EBN book grant represents funds raised for the writing and publication of a reference book entitled "Fundamentals of Cancer Care".

The restricted funds are all held as cash at bank and in hand.

UK Oncology Nursing Society
Corporation Tax Computation
Year ended 31 March 2024

UK Oncology Nursing Society

Year ended 31 March 2024

Contents

Corporation tax computation

A1 Corporation tax

Accounts analysis

B1 Profit and loss account reconciliation

Additional e-filing disclosures

C1 CT600 return values

UK Oncology Nursing Society

Year ended 31 March 2024

A1 Corporation tax

	<u>Tax</u>
	£
Corporation tax payable	<u>nil</u>

UK Oncology Nursing Society

Year ended 31 March 2024

B1 Profit and loss account reconciliation

£

Profit per accounts

—
nil
—

UK Oncology Nursing Society

Year ended 31 March 2024

C1 CT600 return values

	CT600 box	£
<i>Profits before deductions and reliefs</i>		
Profits before other deductions and reliefs	235	-
Profits chargeable to corporation tax	315	nil
<i>Tax calculation</i>		
Corporation tax	430	-
Corporation tax chargeable	440	-
<i>Calculation of tax outstanding or overpaid</i>		
Self-assessment of tax payable before restitution tax and coronavirus support scheme overpayments	525	-
Self-assessment of tax payable	528	nil



Your Company Tax Return

If we send the company a 'Notice' to deliver a Company Tax Return it has to comply by the filing date or we charge a penalty, even if there is no tax to pay.

A return includes a Company Tax Return form, any supplementary pages, accounts, computations and any relevant information. The CT600 Guide tells you how the return must be formatted and delivered. It contains general information you may need to deliver your return, links to more detailed advice and box-by-box guidance for this form and the supplementary pages.

The forms in the CT600 series set out the information we need and provide a standard format for calculations.

Company information

1	Company name	UK Oncology Nursing Society									
2	Company registration number	06996552									
3	Tax reference	9814927182									
4	Type of company	8									

Northern Ireland (NI)

Put an 'X' in the appropriate boxes below					
5	NI trading activity	<input type="checkbox"/>	6	SME	<input type="checkbox"/>
7	NI employer	<input type="checkbox"/>	8	Special circumstances	<input type="checkbox"/>

About this return

This is the tax return for the company named above, for the period below			
30	from DD MM YYYY	35	to DD MM YYYY
01042023		31032024	
Put an 'X' in the appropriate boxes below			
40	A repayment is due for this return period	<input type="checkbox"/>	
45	Claim or relief affecting an earlier period	<input type="checkbox"/>	
50	Making more than one return for this company now	<input type="checkbox"/>	
55	This return contains estimated figures	<input type="checkbox"/>	
60	Company part of a group that is not small	<input type="checkbox"/>	
65	Notice of disclosable avoidance schemes	<input type="checkbox"/>	
Transfer pricing			
70	Compensating adjustment claimed	<input type="checkbox"/>	
75	Company qualifies for SME exemption	<input type="checkbox"/>	

About this return - continued

Accounts and computations		
80	I attach accounts and computations for the period to which this return relates	<input checked="" type="checkbox"/>
85	I attach accounts and computations for a different period	<input type="checkbox"/>
90	If you're not attaching the accounts and computations, explain why	<div></div>
Supplementary pages enclosed		
95	Loans and arrangements to participants by close companies - form CT600A	<input type="checkbox"/>
100	Controlled foreign companies, foreign permanent establishment exemptions, hybrid and other mismatches - form CT600B	<input type="checkbox"/>
105	Group and consortium - form CT600C	<input type="checkbox"/>
110	Insurance - form CT600D	<input type="checkbox"/>
115	Charities and Community Amateur Sports Clubs (CASCs) - form CT600E	<input checked="" type="checkbox"/>
120	Tonnage tax - form CT600F	<input type="checkbox"/>
125	Northern Ireland - form CT600G	<input type="checkbox"/>
130	Cross-border royalties - form CT600H	<input type="checkbox"/>
135	Supplementary charge in respect of ring fence trades - form CT600I	<input type="checkbox"/>
140	Disclosure of Tax Avoidance Schemes - form CT600J	<input type="checkbox"/>
141	Restitution tax - form CT600K	<input type="checkbox"/>
142	Research and Development - form CT600L	<input type="checkbox"/>
143	Freeports and Investment Zones - form CT600M	<input type="checkbox"/>
144	Residential Property Developer Tax (RPDT) - form CT600N	<input type="checkbox"/>

Tax calculation - Turnover

145	Total turnover from trade	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
150	Banks, building societies, insurance companies and other financial concerns																				<input type="text"/>	
- put an 'X' in this box if you do not have a recognised turnover and have not made an entry in box 145																						

Income

155	Trading profits	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
160	Trading losses brought forward set against trading profits	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
165	Net trading profits – box 155 minus box 160	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
170	Bank, building society or other interest, and profits from non-trading loan relationships	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
172	Put an 'X' in box 172 if the figure in box 170 is net of carrying back a deficit from a later accounting period														<input type="text"/>	

Income – continued

175	Annual payments not otherwise charged to Corporation Tax and from which Income Tax has not been deducted	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
180	Non-exempt dividends or distributions from non-UK resident companies	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
185	Income from which Income Tax has been deducted	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
190	Income from a property business	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
195	Non-trading gains on intangible fixed assets	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
200	Tonnage tax profits	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
205	Income not falling under any other heading	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>

Chargeable gains

210	Gross chargeable gains	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
215	Allowable losses including losses brought forward	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
220	Net chargeable gains – box 210 minus box 215	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>

Profits before deductions and reliefs

225	Losses brought forward against certain investment income	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>	
230	Non-trade deficits on loan relationships (including interest) and derivative contracts (financial instruments) brought forward set against non-trading profits	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>	
235	Profits before other deductions and reliefs – net sum of boxes 165 to 205 and 220 minus sum of boxes 225 and 230	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	0	•	<input type="text"/>	<input type="text"/>	<input type="text"/>

Deductions and reliefs

240	Losses on unquoted shares	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
245	Management expenses	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
250	UK property business losses for this or previous accounting period	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
255	Capital allowances for the purposes of management of the business	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
260	Non-trade deficits for this accounting period from loan relationships and derivative contracts (financial instruments)	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>

Deductions and Reliefs - continued

263

Carried forward non-trade deficits from loan relationships and derivative contracts (financial instruments)

£

•

0

0

265

Non-trading losses on intangible fixed assets

£

•

0

0

275

Total trading losses of this or a later accounting period

£

•

0

0

280

Put an 'X' in box 280 if amounts carried back from later accounting periods are included in box 275

285

Trading losses carried forward and claimed against total profits

£

•

0

0

290

Non-trade capital allowances

£

•

0

0

295

Total of deductions and reliefs
- total of boxes 240 to 275, 285 and 290

£

•

0

0

300

Profits before qualifying donations and group relief
- box 235 minus box 295

£

0

•

0

0

305

Qualifying donations

£

•

0

0

310

Group relief

£

•

0

0

312

Group relief for carried forward losses

£

•

0

0

315

Profits chargeable to Corporation Tax
- box 300 minus boxes 305, 310 and 312

£

0

•

0

0

320

Ring fence profits included

£

•

0

0

325

Northern Ireland profits included

£

•

0

0

Tax calculation

326

Number of associated companies in this period

327

Number of associated companies in the first financial year

328

Number of associated companies in the second financial year

329

Put an 'X' in box 329 if the company is chargeable at the small profit rate or is entitled to marginal relief

Enter how much profit has to be charged and at what rate

	Financial year (yyyy)		Amount of profit		Rate of tax %		Tax
330		335	£	340		345	£ p
		350	£	355		360	£ p
		365	£	370		375	£ p
380		385	£	390		395	£ p
		400	£	405		410	£ p
		415	£	420		425	£ p

Tax calculation - continued

Corporation Tax - total of boxes 345, 360, 375, 395, 410 and 425	430	£																0	•	0	0
Marginal relief	435	£																	•		
Corporation Tax chargeable - box 430 minus box 435	440	£																0	•	0	0

Reliefs and deductions in terms of tax

445	Community Investment Tax Relief	£																	•		
450	Double Taxation Relief	£																	•		
455	Put an 'X' in box 455 if box 450 includes an underlying rate relief claim																				
460	Put an 'X' in box 460 if box 450 includes an amount carried back from a later period																				
465	Advance Corporation Tax	£																	•		
470	Total reliefs and deduction in terms of tax - total of boxes 445, 450 and 465	£																	•		

Coronavirus support schemes and overpayments (see CT600 Guide for definitions)

471	Coronavirus Job Retention Scheme (CJRS) received	£																	•		
472	CJRS entitlement	£																	•		
473	CJRS overpayment already assessed or voluntary disclosed	£																	•		
474	Other coronavirus overpayments	£																	•		

Energy levies

986	Energy (Oil and Gas) Profits Levy (EOGPL) amounts liable	£																	•	0	0
987	Electricity Generator Levy (EGL) exceptional generation receipts	£																	•	0	0

Calculation of tax outstanding or overpaid

475	Net Corporation Tax liability - box 440 minus box 470	£																	•	0	0
480	Tax payable on loans and arrangements to participants	£																	•		
485	Put an 'X' in box 485 if you completed box A70 in the supplementary pages CT600A																				
490	Controlled Foreign Companies (CFC) tax payable	£																	•		
495	Bank levy payable	£																	•		
496	Bank surcharge payable	£																	•		
497	Residential Property Developer Tax (RPDT) payable	£																	•		

Calculation of tax outstanding or overpaid - continued

500	CFC tax, bank levy, bank surcharge and RPDT payable – total of boxes 490, 495, 496 and 497	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
501	EOGPL payable	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
502	EGL payable	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
505	Supplementary charge (ring fence trades) payable	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
510	Tax chargeable – total of boxes 475, 480, 500, 501, 502 and 505	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	0	.	<input type="text"/> <input type="text"/> <input type="text"/>
515	Income Tax deducted from gross income included in profits	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
520	Income Tax repayable to the company	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
525	Self-assessment of tax payable before restitution tax and coronavirus support scheme overpayments – box 510 minus box 515	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	0	.	<input type="text"/> <input type="text"/> <input type="text"/>
526	Coronavirus support schemes overpayment now due – total of boxes 471 and 474 minus boxes 472 and 473	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
527	Restitution tax	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
528	Self-assessment of tax payable – total of boxes 525, 526 and 527	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	0	.	<input type="text"/> <input type="text"/> <input type="text"/>

Tax reconciliation

530	Research and Development credit	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
535	(Not currently used)	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
540	Creatives tax credit	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
545	Total of Research and Development credit and creative tax credit – total box 530 to 540	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
550	Land remediation tax credit	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
555	Life assurance company tax credit	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
560	Total land remediation and life assurance company tax credit – total box 550 and 555	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
565	Capital allowances first-year tax credit	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
570	Surplus Research and Development credits or creative tax credit payable – box 545 minus box 525	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
575	Land remediation or life assurance company tax credit payable – total of boxes 545 and 560 minus boxes 525 and 570	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>

Tax reconciliation - continued

580	Capital allowances first-year tax credit payable – boxes 545, 560 and 565 minus boxes 525, 570 and 575	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
585	Ring fence Corporation Tax included	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
586	NI Corporation Tax included	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
590	Ring fence supplementary charge included	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
595	Tax already paid (and not already repaid)	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
600	Tax outstanding – box 525 minus boxes 545, 560, 565 and 595	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
605	Tax overpaid including surplus or payable credits – total sum of boxes 545, 560, 565 and 595 minus 525	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
610	Group tax refunds surrendered to this company	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>
615	Research and Development expenditure credits surrendered to this company	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	.	<input type="text"/>	<input type="text"/>

Exporter information

During the return period, did the company export goods and/or services to individuals, enterprises or organisations outside the United Kingdom (UK)?

616 Yes – goods ☐

617 Yes – services ☐

618 No – neither ☐

Indicators and information

620	Franked investment income/Exempt ABGH distributions	£ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> . <input type="text"/> <input type="text"/>
625	Number of 51% group companies	<input style="width: 100px;" type="text"/>
Put an 'X' in the relevant boxes, if in the period, the company:		
630	should have made (whether it has or not) instalment payments as a large company under the Corporation Tax (Instalment Payments) Regulations	<input style="width: 30px;" type="checkbox"/>
631	should have made (whether it has or not) instalment payments as a very large company under the Corporation Tax (Instalment Payments) Regulations	<input style="width: 30px;" type="checkbox"/>
635	is within a group payments arrangement for the period	<input style="width: 30px;" type="checkbox"/>
640	has written down or sold intangible assets	<input style="width: 30px;" type="checkbox"/>
645	has made cross-border royalty payments	<input style="width: 30px;" type="checkbox"/>
647	Eat Out to Help Out Scheme: reimbursed discounts included as taxable income	£ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> . <input type="text"/> <input type="text"/>

Research and Development (R&D) or creative enhanced expenditure and tax reliefs

Land remediation enhanced expenditure

Information about capital allowances and balancing charges/disposal values

Allowances and charges in the calculation of trading profits and losses

UK Oncology Nursing Society

Allowances and charges in the calculation of trading profits and losses - continued

	Capital allowances	Disposal value
Electric charge-points	713 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	714 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>
Enterprise zones	721 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	722 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>
Zero emissions goods vehicles	723 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	724 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>
Zero emissions cars	726 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	727 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>

Allowances and charges not included in the calculation of trading profits and losses

	Capital allowances	Balancing charges
Annual investment allowance	735 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	
Structures and buildings	736 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	
Full expensing	733 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	734 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>
Business premises renovation	740 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	745 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>
Machinery and plant – super-deduction	741 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	742 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>
Machinery and plant – special rate allowance	743 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	744 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>
Other allowances and charges	750 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	755 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>
	Capital allowances	Disposal value
Electric charge-points	737 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	738 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>
Enterprise zones	746 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	747 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>
Zero emissions goods vehicles	748 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	749 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>
Zero emissions cars	751 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	752 £ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>

Qualifying expenditure

760	Machinery and plant on which first year allowance is claimed	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
765	Designated environmentally friendly machinery and plant	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
770	Machinery and plant on long-life assets and integral features	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
771	Structures and buildings	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
772	Machinery and plant – super-deduction	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
773	Machinery and plant – special rate allowance	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
775	Other machinery and plant	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>

Losses, deficits and excess amounts

Amount arising

	Amount		Maximum available for surrender as group relief
Losses of trades carried on wholly or partly in the UK	780 £ <input type="text"/>		785 £ <input type="text"/>
Losses of trades carried on wholly outside the UK	790 £ <input type="text"/>		
Non-trade deficits on loan relationships and derivative contracts	795 £ <input type="text"/>		800 £ <input type="text"/>
UK property business losses	805 £ <input type="text"/>		810 £ <input type="text"/>
Overseas property business losses	815 £ <input type="text"/>		
Losses from miscellaneous transactions	820 £ <input type="text"/>		
Capital losses	825 £ <input type="text"/>		
Non-trading losses on intangible fixed assets	830 £ <input type="text"/>		835 £ <input type="text"/>

Excess amounts

	Amount		Maximum available for surrender as group relief
Non-trade capital allowances		840 £ <input type="text"/>	
Qualifying donations		845 £ <input type="text"/>	
Management expenses	850 £ <input type="text"/>		855 £ <input type="text"/>

Northern Ireland information

856	Amount of group relief claimed which relates to NI trading losses used against rest of UK/mainstream profits	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
857	Amount of group relief claimed which relates to NI trading losses used against NI trading profits	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
858	Amount of group relief claimed which relates to rest of UK/mainstream losses used against NI trading profits	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>

Overpayments and repayments

Small repayments

860	Do not repay sums of	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>	or less.
Read the overpayments and repayments section of the Company Tax Return Guide for specific guidance on when and how to make an entry in this box.																				

Repayments for the period covered by this return

865	Repayment of Corporation Tax	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
870	Repayment of Income Tax	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
875	Payable Research and Development tax credit	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
880	Payable Research and Development expenditure credit	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
885	Payable creative tax credit	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
890	Payable land remediation or life assurance company tax credit	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
895	Payable capital allowances first-year tax credit	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>

Surrender of tax refund within group

Including surrenders under the Instalment Payments Regulations																			
900	The following amount is to be surrendered	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>
Put an 'X' in the appropriate boxes below																			
the joint Notice is attached																			
																		905	<input type="text"/>
or																			
will follow																			
																		910	<input type="text"/>
915	Please stop repayment of the following amount until we send you the Notice	£	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	•	<input type="text"/>	<input type="text"/>	<input type="text"/>

Bank details (for a person to whom a repayment is to be made)

920

Name of bank or building society

925

Branch sort code

930

Account number

935

Name of account

940

Building society reference

Payments to a person other than the company

945

Complete the authority below if you want the repayment to be made to a person other than the company
I, as (enter status - for example, company secretary, treasurer, liquidator or authorised agent)

950

of (enter company name)

955

authorise (enter name)

960

of address (enter address)

965

Nominee reference

to receive payment on company's behalf

970

Name

Declaration

Declaration

I declare that the information I have given on this Company Tax Return and any supplementary pages is correct and complete to the best of my knowledge and belief.

I understand that giving false information in the return, or concealing any part of the company's profits or tax payable, can lead to both the company and me being prosecuted.

975

Name

DR K CAMPBELL

980

Date DD MM YYYY

985

Status

Director

CT600(2024) Version 3

Page 12

HMRC 04/24

UK Oncology Nursing Society



Guidance

Guidance about when and how to complete this supplementary page can be found in the CT600 Guide.

For further information read *What supplementary pages do I need to complete and include as part of the Company Tax Return?* to find out what supplementary pages you need to complete.

Also, read the *Important points about all supplementary pages* and *CT600E – Charities and Community Amateur Sports Clubs (CASCs)* for further guidance about completing this supplementary page.

Company information

E1	Company name (name of charity or CASC)	UK Oncology Nursing Society
E2	Tax reference	9 8 1 4 9 2 7 1 8 2
Period covered by this supplementary page (cannot exceed 12 months)		
E3	from DD MM YYYY	0 1 0 4 2 0 2 3
E4	to DD MM YYYY	3 1 0 3 2 0 2 4

Claims to exemption (this section should be completed in all cases)

Charity/CASC repayment reference	E5	
Charity Commission registration number, or OSCR number (if applicable)	E10	1136972
Put an 'X' in the relevant box if during the period covered by these supplementary pages:		
The company was a charity/CASC and is claiming exemption from all tax on all or part of its income and gains (Also put an 'X' in box E15 if the company was a charity/CASC but had no income or gains in the period)	E15	X
All income and gains are exempt from tax and have been, or will be, applied for charitable or qualifying purposes only	E20	X
Some of the income and gains may not be exempt or have not been applied for charitable or qualifying purposes only, and I have completed form CT600	E25	
I claim exemption from tax		
Name	E30	DR K CAMPBELL
Status	E35	Director
Date DD MM YYYY	E40	

UK Oncology Nursing Society

Put an 'X' in the box if during the period covered by these supplementary pages you have over claimed tax.

--	--

Non-exempt amounts should be entered on form CT600 in the appropriate boxes.

HMRC 04/15

Information required

Charity/CASC assets

Disposals in period
(total consideration received)

Held at the end of the period
(use accounts figures)

Tangible fixed
assets

E130 £

E135 £

UK investments
(excluding
controlled companies)

E140 £

E145 £

Shares in,
and loans to,
controlled companies

E150 £

E155 £

Overseas
investments

E160 £

E165 £

Loans and non-trade debtors

E170 £

Other current assets

E175 £ 2 0 4 9 0 3

Qualifying investments and loans

Applies to charities only. See CT600 Guide

E180

Value of any non-qualifying investments and loans

Applies to charities only. See CT600 Guide

E185 £

Number of subsidiary or associated companies the charity
controls at the end of the period. Exclude companies that
were dormant throughout the period

E190